(CST-2032 + nadolol) by CuraSen Therapeutics for Dementia: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(CST-2032 + nadolol) overview

A fixed-dose combination of CST-2032 and nadolol (CST-107) is under development for the treatment of mild cognitive impairment or mild dementia due to either Parkinson’s or Alzheimer’s disease. The drug combination is administered orally. It acts by targeting beta-2 adrenoceptor.

CuraSen Therapeutics overview

CuraSen Therapeutics is developing drugs targeting a novel mechanism in the brain to restore function, improve symptoms and modify disease in a range of neurodegenerative diseases, including orphan disorders as well as Parkinson’s Disease and Alzheimer’s Disease.

For a complete picture of (CST-2032 + nadolol)’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.